More Articles

Cost savings and use of generics in Europe Reports | Posted 04/04/2014

Generics provide significant savings for the healthcare systems, as well as increased access to medicines, in the European Union (EU). This is according to a presentation by Mr Victor Lino Mendonça...

US FTC hopes to collect US$1 billion from pay-for-delay settlement Pharma News | Posted 04/04/2014

The US Federal Trade Commission (FTC) is looking to collect more than US$1 billion from a settlement with pharmaceutical companies it has sued for their part in what the FTC terms ‘pay-for-delay’ d...

Prescribers, pharmacists and patients in Turkey believe generics differ from originators Generics/Research | Posted 04/04/2014

A study carried out by Toklu and co-authors from the University of Istanbul, Turkey, has shown that many prescribers, pharmacists and patients in Turkey believe that generics differ from their orig...

Alvotech and Finesse enter into biosimilars collaboration Biosimilars/News | Posted 04/04/2014

Iceland-based biopharmaceutical company Alvotech and US-based bio-process management company Finesse Solutions (Finesse) announced on 14 March 2014 that they had entered into a partnership for bio-...

The generics market in China Reports | Posted 04/04/2014

Market access barriers remain the main challenge for generics in China, according to a presentation by Xianghong Shao given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual...

Dr Reddy’s launches generic amlodipine/atorvastatin Generics/News | Posted 04/04/2014

Indian generics giant Dr Reddy’s announced on 27 March 2014 the launch of its generic amlodipine/atorvastatin tablets in the US.

European doctors have insufficient knowledge of biosimilars Reports | Posted 28/03/2014

The Alliance for Safe Biologic Medicines (ASBM), which represents patients and physicians, as well as originator biological and biosimilar medicines companies in the US, published results of a surv...

The non-financial benefits of generics substitution Generics/Research | Posted 28/03/2014

Switching between different generic brands of metformin is a good cost-effective approach that does not adversely affect the quality of care for patients with type 2 diabetes, according to the resu...